Chronic Kidney Disease
Conditions
Brief summary
This is a randomized, open-label, parallel-design study to be conducted at 75 centers within the United States. The study will be described to hemodialysis patients. Informed consent will be obtained and the inclusion/exclusion criteria reviewed. Eligible patients will be randomized to receive either Renagel or a calcium-based binder. Starting from the randomization date, mortality data including survival, death date and cause of death (vital status information) and morbidity data including hospitalization date will be recorded for all patients. These data will be collected until the end of the study (December 31, 2004, ± 2 weeks). Patients completing or terminating from the study will return to the phosphate binder prescribed by their usual healthcare provider.
Interventions
Sponsors
Genzyme, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients must be 18 years of age or older, * on dialysis for more than 3 months, * require phosphate binder therapy, * have Medicare as their primary insurance.
Exclusion criteria
* dysphagia, * swallowing disorders, * severe gastrointestinal motility disorders, * bowel obstruction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy will be evaluated based on a comparison of the association of Renagel use versus calcium-based phosphate binder use on all-cause mortality, cause-specific mortality (cardiovascular, infection, other), and all-cause hospitalization. | — |
| Safety will be assessed based on an evaluation of related serious adverse events. | — |
Countries
Puerto Rico, United States
Outcome results
None listed